Veröffentlicht seit 1. Dezember 1980

Drug Metabolism and Personalized Therapy

Official journal of the European Society of Pharmacogenomics and Personalised Therapy

ISSN: 2363-8915

Editor-in-Chief: Adrián Llerena

Manuskript einreichen

Über diese Zeitschrift

Objective

Drug Metabolism and Personalized Therapy (DMPT) is the official journal of the European Society of Pharmacogenomics and Personalised Therapy (ESPT). DMPT offers up-to-date research articles, reviews and opinion papers from the broad field of personalized therapy and pharmacogenomics. Specifically, it covers the following fields: pharmacogenetics, pharmacogenomics and drug metabolism research, dealing with established, new and potential drugs, herbal medicinal products, environmentally toxic chemicals, the mechanisms by which drugs and herbs can interact with each other and with biological systems, and the pharmacological and toxicological consequences of these interactions, as well as drug metabolism and excretion. More generally, it is concerned with the area of therapeutic individualization, particularly on the basis of pharmacogenetics, with regards to the use of pharmaceuticals and herbal medicine, including traditional medicine.
DMPT is an international scientific single-blind peer-review journal, which is issued quarterly with 8-10 articles per issue. The Journal publishes only English-language articles.

Please submit your manuscript here

Topics

drug metabolizing enzymes
pharmacogenetics and pharmacogenomics
biochemical pharmacology
molecular pathology
clinical pharmacology
pharmacokinetics and drug-drug interactions
immunopharmacology
neuropsychopharmacology
herbal medicine and traditional medicine

Article formats
Research Articles, Reviews and Mini Reviews, Opinion Papers, Short Communications, letters to the Editor, Case Reports, Editorials

Ihre Vorteile

Your benefits:

Comprehensive approach to drug metabolism research
State-of-the-art research results
Renowned editorial board
High quality peer-review

Vorherige Titel

Founded in 1981 until 2014: Drug Metabolism and Drug Interactions

From 2015 onwards: Drug Metabolism and Personalized Therapy

Other publications in the field

Abstracting und Indexing

Drug Metabolism and Personalized Therapy ist in den folgenden Services indiziert:

Baidu Scholar
Cabells Journalytics
CABI (over 50 subsections)
Chemical Abstracts Service (CAS) - CAplus
Chemical Abstracts Service (CAS) - SciFinder
CNKI Scholar (China National Knowledge Infrastructure)
CNPIEC - cnpLINKer
Dimensions
EBSCO (relevant databases)
EBSCO Discovery Service
EMBASE
Genamics JournalSeek
Google Scholar
Japan Science and Technology Agency (JST)
J-Gate
JournalGuide
JournalTOCs
KESLI-NDSL (Korean National Discovery for Science Leaders)
Medline
MyScienceWork
Naver Academic
Naviga (Softweco)
Norwegian Register for Scientific Journals, Series and Publishers
Primo Central (ExLibris)
ProQuest (relevant databases)
Publons
PubMed
PubsHub
QOAM (Quality Open Access Market)
ReadCube
Reaxys
Scilit
SCImago (SJR)
SCOPUS
Semantic Scholar
Sherpa/RoMEO
Summon (ProQuest)
TDNet
TEMA Technik und Management
Text Mining
Ulrich's Periodicals Directory/ulrichsweb
WanFang Data
Web of Science - Biological Abstracts
Web of Science - BIOSIS Previews
Web of Science - International Pharmaceutical Abstracts
Web of Science - Prous Science Integrity
WorldCat (OCLC)
X-MOL
Yewno Discover

Zusatzmaterial

Fachgebiete

Externe Links

Band 38 Heft 3

September 2023

Öffentlich zugänglich 15. September 2023

Frontmatter

Seiten: i-ii

PDF downloaden

Editorial

Öffentlich zugänglich 24. August 2023

Relevance of personalized medicine for improving traditional medicine

Ingrid Fricke-Galindo, Adrián LLerena

Seiten: 209-210

PDF downloaden

Review

Öffentlich zugänglich 1. Juni 2023

Mechanistic role and potential of Ayurvedic herbs as anti-aging therapies

Kirti Raina, Ruchika Kumari, Palak Thakur, Rohit Sharma, Randeep Singh, Abhinay Thakur, Vikas Anand, Rohit Sharma, Ashun Chaudhary

Seiten: 211-226

Mehr PDF downloaden

Abstract

Introduction Medicinal plants and herbs are the most important part of the Ayurveda. The term Rasayana in Charaka Samhita confers long life, youthfulness, strong body, freedom from diseases and the plants mentioned in Rsayana possess antiaging property. Aging is the collective term used for the complex detrimental physiological changes that reduce the functional ability of the cell. Oxidative stress, telomeres shortening, inflammation, and mitochondrial dysfunction are the main factors that regulate the aging process. Chronological aging is an irreversible process but the factors causing biological aging can be controlled. Ayurvedic herbs are better for the management of age-related problems. There are several natural bioactive agents present in plants that can delay the aging process in humans. They trigger actions like enhancing gene longevity and telomerase activity, ROS scavenging furthermore regeneration of tissues. Content The plants mentioned in the Rasayana of Ayurveda have antiaging potential and can be used to solve modern problems related to aging. Some Ayurvedic plants and their antiaging potential has explained in this review. The main causes of aging, medicinal plants and their use as potential antiaging mediator are covered in this study. Summary The process of aging is still an enigma. It is a complex, irretrievable, dynamic process that involves a number of factors and is subject to a number of environmental and genetic influences. Rasayana aspect has not been much investigated in clinical trials. Aging is considered to result from free radical damage. According to Charaka, Rasayana drugs open the partially or fully blocked channels. Many Rasayanas show free radical scavenging activity and has the potential to mitigate the effects of aging. It gives an overview of the significance of Ayurvedic medicinal plants as a source of inspiration and the use of these plants as remedies for antiaging. Outlook This study briefly outlooks the causes of aging and how medicinal plants can be used to reverse the aging process. In this study, we discussed the antiaging potential and mechanistic roles of Ayurvedic herbs. These herbs have the properties to slow down the natural process of aging and can successfully manage common age-related problems.

Original Articles

Öffentlich zugänglich 26. April 2023

Safety, immunogenecity and effectiveness of ChAdOx1 nCoV-19 vaccine during the second wave of pandemic in India: a real-world study

Preeti Chavan, Rajashree Dey, Renita Castelino, Akshay Kamble, Pratik Poladia, Rajani Bagal, Monica Jadhav, Aditi Shirsat, Ashish Chavan, Sachin Dhumal, Sharath Kumar, Manjunath Nookala Krishnamurty, Vivek Bhat, Atanu Bhattacharjee, Vikram Gota

Seiten: 227-236

Mehr PDF downloaden

Abstract

Objectives This real-world study was conducted to assess the adverse effects following immunization (AEFI) and immunogenicity of ChAdO×1 nCoV-19 vaccine in terms of neutralising antibody titers and to study the effects of covariates such as age, sex, comorbidities and prior COVID status on these outcomes. Also, the effectiveness of the vaccine based on interval between the two doses was also investigated. Methods A total of 512 participants (M/F=274/238) aged 35(18–87) years comprising a mixed population of healthcare workers, other frontline workers and general public were enrolled between March and May 2021. Records for adverse events if any were collected telephonically by following up with participants up to 6 months post first dose and graded as per Common Terminology Criteria for Adverse Events (CTCAE) version 5. Blood samples for measuring antibody titers against the receptor binding domain (RBD) were collected serially using a convenient sampling strategy up to 6 months after the first dose. Data on breakthrough COVID infection was collected telephonically till December 2021. Results Incidence of local reactions was higher after first dose at 33.4 % (171/512) compared to those after second dose at 12.9 % (66/512). Commonest side effect observed was injection site pain after the first (87.1 %; 149/171) and second (87.9 %; 56/66) dose respectively. Among systemic reactions, fever was the most common manifestation followed by myalgia and headache. Female sex (p<0⸱001) and age less than 60 years (p<0⸱001) had significantly higher predilection for systemic toxicities. Age ≤60 years (p=0.024) and prior-COVID (p<0.001) were found to be significantly associated with higher antibody titers, however, no association was found between these variables and breakthrough COVID infection. Longer spacing between the doses (≥6 weeks) was found to offer better protection against breakthrough infection compared to a spacing of 4 weeks. All breakthroughs were mild-moderate in severity, not requiring hospitalization. Conclusions The ChAdOx1 nCov-19 vaccine is apparently safe and effective against SARS-CoV-2 virus infection. Prior COVID infection and younger age group achieve higher antibody titers, but no additional protection. Delaying the second dose up to at least 6 weeks is more effective compared to shorter spacing between doses.

4. April 2023

Evaluation of the efficacy of topical Terminalia chebula Retz. with vinegar in the treatment of tinea corporis: a non-inferiority randomized controlled trial

Sumayya Tasneem Parapur, Nazim Husain, Mohd Khalid, Saba Abdul Razzaq Mamdapur, Khan Ameer Kauser Khan

Seiten: 237-245

Mehr

Abstract

Objectives Unani physicians have suggested a wide range of anti-dermatophytic remedies, although the scientific evidence is scarce. Thus, the efficacy and safety of Terminalia chebula Retz. fruit powder mixed with vinegar was compared with terbinafine hydrochloride 1% cream in the treatment of tinea corporis in order to establish the non-inferiority of test drugs. Methods The primary outcome measures were change in the presence or absence of hyphae on KOH mount test, change in pruritus severity assessed on 100 mm VAS and change in physician’s global assessment. Secondary outcome measure was change in the dermatology life quality index (DLQI). Hemograms, serum creatinine, serum bilirubin, and random blood sugar levels were measured at the baseline and after treatment to ensure the safety of the interventions. Results A per-protocol analysis was done on 40 participants (21 in the test group and 19 in the control group). The observed differences in the primary and secondary outcomes between the test and control groups were greater than the non-inferiority margin, signifying that the test drugs were not inferior. Conclusions It may be inferred that the trial drug Terminalia chebula Retz. fruit powder mixed with vinegar is not inferior to terbinafine hydrochloride cream in the treatment of tinea corporis.

19. Mai 2023

Pharmacogenetic predictors of development of secondary to enalapril dry cough in hypertensive patients

Ivan V. Sychev, Natalia P. Denisenko, Anastasiya A. Kachanova, Anna V. Lapshtaeva, Ludmila N. Goncharova, Karin B. Mirzaev, Dmitry A. Sychev

Seiten: 247-254

Mehr

Abstract

Objectives Development of the secondary to ACEI cough leads to discontinuation of the drugs of this group. Assessing the safety of the ACEIs with further development of customized approaches for their administration is a major scientific and practical problem. The objective of this study was to assess the association of the genetic markers with the development of the adverse drug reaction in the form of secondary to enalapril dry cough in the patients with essential arterial hypertension. Methods Study involved 113 patients with the secondary to enalapril cough and 104 patients without development of the secondary to enalapril adverse drug reaction. Results The patients carriers of the genotype AA rs2306283 of gene SLCO1B1 had 2-fold higher odds of developing the dry cough than those with the genotypes AG and GG (ОR=2.01, 95%CI=1.10–3.66, р=0.023). Similarly, the patients heterozygous for rs8176746 of gene АВО had 2.3-fold higher odds of developing the ADR in the form of dry cough than the carriers of the genotypes GG and TT (ОR=2.30, 95%CI=1.24–4.29, р=0.008). Conclusions Statistically significant association between the development of the ADR in the form of secondary to enalapril dry cough and polymorphisms rs2306283 of gene SLCO1B1 and rs8176746 of gene ABO was revealed.

30. Juni 2023

Genetic markers associated with adverse reactions of radioiodine therapy in thyroid cancer patients

Natalia P. Denisenko, Anastasia A. Kachanova, Ivan V. Sychev, Gregory N. Shuev, Oksana M. Perfilieva, Reis H. Mukhamadiev, Ruslan E. Kazakov, Olga I. Milyutina, Olga V. Konenkova, Sergey A. Ryzhkin, Elena M. Zhmaeva, Sergey L. Kirienko, Dmitriy V. Ivashchenko, Irina V. Bure, Alexander S. Ametov, Irina V. Poddubnaya, Karin B. Mirzaev, Dmitry A. Sychev

Seiten: 255-265

Mehr

Abstract

Objectives Radioactive iodine therapy is considered for patients with certain clinicopathological factors that predict a significant risk of recurrence, distant metastases of thyroid cancer or disease-specific mortality. The aim of the study was to investigate the association between polymorphisms of genes, products of which are involved in the processes of DNA damage response and autophagy, and the adverse reactions of radioiodine therapy in thyroid cancer patients. Methods The study included 181 patients (37 men, 144 women; median age 56 [41; 66.3] years) with histologically confirmed thyroid cancer and a history of thyroidectomy who received radioiodine therapy. NFKB1 , ATM , ATG16L2 , ATG10 , TGFB1 , and TNF polymorphisms were determined by allele-specific realtime-PCR. Results The frequency of adverse reactions was the following: gastrointestinal symptoms – 57.9 %, local symptoms – 65.8 %, cerebral symptoms – 46.8 %, fatigue – 54.4 %; signs of sialoadenitis six months after radioiodine therapy – 25.2 %. TT genotype carriers of ATG10 rs1864183 had higher frequency of gastrointestinal symptoms (vs. CC+CT), the CC genotype carriers of ATG10 rs10514231 had significantly more frequent cerebral symptoms (vs. CT+TT), as well as AA genotype carriers of TGFB1 rs1800469 (vs. AG+GG). CC genotype of ATG10 rs10514231 increased the incidence of radioiodine-induced fatigue, whereas GA genotype of the ATM rs11212570 had a protective role against fatigue. TGFB1 rs1800469 was associated with signs of sialoadenitis six months after radioiodine therapy. Conclusions Genetic factors may contribute to the occurrence of adverse reactions of radioiodine therapy in thyroid cancer patients.

13. März 2023

Lack of exposure to pharmacogenomics education among the health care providing students in the West Bank of Palestine

Yazun Jarrar, Rami Musleh, Anas Hamdan, Mustafa Ghanim, Malik Alqub, Sara Abudahab

Seiten: 267-272

Mehr

Abstract

Objectives Evaluating the knowledge in pharmacogenomics (PGx) is the first step toward the implementation of PGx testing in clinical practice. This survey aimed to evaluate the knowledge of PGx testing among healthcare providing students at the top-ranked university in the West Bank of Palestine. Methods First an online questionnaire consisting of 30 questions regarding the demographic, knowledge, and attitude toward pharmacogenomics testing was structured and validated. Then the questionnaire was distributed to 1,000 current students from different fields. Results 696 responses was received. The results showed that almost half of the participants (n=355, 51.1%) have never took any courses about PGx during their university training. Only 81 (11.7%) of the students who took the PGx course stated that it helped them understanding how genetic variations affect drug response. The majority of the students were uncertain (n=352, 50.6%) or disagreed (n=143, 20.6%) that the lectures during university education described the effects of genetic variants on drug response. Although most of the students (70–80%) answered that genetic variants can indeed affect the drug’s response, only 162 students (23.3%) responded that VKORC1 and CYP2C9 genotypes influence the response to warfarin. In addition, only 94 (13.5%) students were aware that many medicine labels include clinical information about PGx testing provided by the FDA. Conclusions It is concluded from the results of this survey that there is a lack of exposure to PGx education associated with poor knowledge of PGx testing among the healthcare providing students in the West Bank of Palestine. It is recommended to include and improve the lectures and courses regarding PGx as this will have a major impact on precision medicine.

19. April 2023

Development and validation wise assessment of genotype guided warfarin dosing algorithm in Indian population

Aishwarya Anand, Rupesh Kumar, Swati Sharma, Ankur Gupta, Rajesh Vijayvergiya, Saurabh Mehrotra, Basant Kumar, Deepesh Lad, Amol N. Patil, Nusrat Shafiq, Samir Malhotra

Seiten: 273-279

Mehr

Abstract

Objectives A study was conducted to develop and validate the warfarin pharmacogenetic dose optimization algorithm considering the clinical pharmacogenetic implementation consortium (CPIC) recommendations for the Asian ethnicity population. Methods The present prospective observational study recruited warfarin-receiving patients. We collected a three ml blood sample for VKORC1, CYP2C9*2, CYP2C9*3, and CYP4F2 polymorphism assessment during the follow-up visits. Clinical history, sociodemographic and warfarin dose details were noted. Results The study recruited 300 patients (250 in derivation and 50 in validation timed cohort) receiving warfarin therapy. The baseline characteristics were similar in both cohorts. BMI, presence of comorbidity, VKORC1, CYP2C9*2, and CYP2C9*3 were identified as covariates significantly affecting the warfarin weekly maintenance dose (p<0.001 for all) and the same were included in warfarin pharmacogenetic dose optimization algorithm building. The algorithm built-in the present study showed a good correlation with Gage (r=0.57, p<0.0001), and IWPC (r=0.51, p<0.0001) algorithms, widely accepted in western side of the globe. The receiver operating characteristic curve analysis showed a sensitivity of 73 %, a positive predictive value of 96 %, and a specificity of 89 %. The algorithm correctly identified the validation cohort’s warfarin-sensitive, intermediate reacting, and resistant patient populations. Conclusions Validation and comparisons of the warfarin pharmacogenetic dose optimization algorithm have made it ready for the clinical trial assessment.

16. März 2023

Exploratory quasi-experimental study of anti-arthritic activity of Ayurvedic polyherbal formulation, Abha Guggulu in osteoarthritis patients

Mrinmayee Hedaoo, Trupti Patil-Bhole, Rohit Sharma, Madhavi Mahajan

Seiten: 281-288

Mehr

Abstract

Objectives Abha Guggulu (AG) is a traditional Ayurvedic herbal formulation used for treating joint disorders and bone fractures. Individually, the ingredients are known for their promising anti-inflammatory and rejuvenating actions. The present study attempts to explore the anti–arthritic potential of AG through an exploratory clinical trial. Methods The study was conducted using a quasi-experimental model. The clinical trial has been registered in Clinical Trials Registry of India (registration number: CTRI/2019/09/021354). Osteoarthritis patients of both genders (n=12, 40–70 years age group), meeting the inclusion/exclusion criteria, were recruited in the single arm study. AG was administered in tablet form in a dose of 1.5 g, twice daily. The WOMAC score was used as a primary outcome measure. The WOMAC scale of patients was recorded on 0th, 15th and 30th days of treatment. Results At the end of treatment, there was a significant difference in the scores of the outcome measure. As per WOMAC total score, participants were significantly improved (p=0.002) after consuming the drug for 1 month. Conclusions Overall, the data indicates significant improvement of subjects in both scales and objective measures used for assessment purposes. There were no adverse drug reactions reported during the trial. AG may be used as a safe and effective supplement to reduce symptoms of osteoarthritis. The clinical efficacy of the formulation might be mediated through the synergistic blend of herbal bioactive compounds from AG.

Letter to the Editor

Öffentlich zugänglich 17. April 2023

Ayurvedic medicines in alleviating the symptoms of SARS-CoV-2 omicron variant in North Indian population: a regional genomic study

Konduru Rama Chandra Reddy, Chetan Sahni, Royana Singh, Hari Chandana, Rohit Sharma

Seiten: 289-291

PDF downloaden

Ahead-of-Print / Just-Accepted

Ahead-of-Print / Just-Accepted

Band 38 (2023)

Band 37 (2022)

Band 36 (2021)

Band 35 (2020)

Band 34 (2019)

Band 33 (2018)

Band 32 (2017)

Band 31 (2016)

Band 30 (2015)

Band 29 (2014)

Band 28 (2013)

Band 27 (2012)

Band 26 (2011)

Band 25 (2010)

Heft 1-4

Band 24 (2009)

Band 23 (2008)

Band 22 (2007)

Band 21 (2006)

Band 20 (2004)

Band 19 (2003)

Band 18 (2001)

Band 16 (2000)

Band 17 (2000)

Heft 1-4

Band 15 (1999)

Band 14 (1998)

Band 13 (1997)

Band 12 (1995)

Band 11 (1994)

Band 10 (1992)

Band 9 (1991)

Band 8 (1990)

Heft 1-2

Band 7 (1989)

Band 6 (1988)

Band 5 (1987)

Band 4 (1982)

Band 3 (1981)

CiteScore	3.4	2022, Scopus (Elsevier B.V., 2023)
SCImago Journal Rank	0.301	2022, SJR (Scimago Lab, 2023; Data Source: Scopus)
Source Normalized Impact per Paper	0.405	2022, CWTS Journal Indicators (CWTS B.V., 2023; Data Source: Scopus)

Weitere Informationen über Zeitschriftenmetriken

Einreichen

Submission
You can easily submit your manuscript online. Simply go to https://mc.manuscriptcentral.com/dmpt and you will be guided through the whole submission and publishing process.

Your benefits of publishing with us

Rapid publication times
No submission and publication fee
Optional Open Access Publication
Free color illustrations
Accepted papers will be published online first as DOI-citable, forward-linked articles for quickest possible visibility for the scientific community
Every article easily discoverable because of SEO and comprehensive abstracting and indexing services
Secure archiving by De Gruyter and the independent archiving service Portico

Submission process

Submission of your manuscript via our submission tool ScholarOne following the Information for Authors
Single-blind peer review process
A decision on your paper is aspired within 2-4 weeks
Accepted articles are published online ahead of print approx. 4 weeks after acceptance

Please note

Manuscripts must be written in clear and concise English
Before submitting your article please have a look at the DMPT Submission Checklist, the Publication Ethics Statement and our copyright agreement
As a condition of submission, the Template for Ethical and Legal Declarations must be customized by the submitting author on behalf of all others and uploaded as a separate Word file. Instructions on how to make declarations can be found here
Once your article is accepted you have the option to publish it open access
Our repository policy allows you to distribute 30 PDF copies of your published article to colleagues (the PDF has to include the information that it is an author's copy). Please also feel free to distribute the link to the online abstract
Please also feel free to distribute the link to the online abstract If you have any general questions please visit our FAQ page for authors
For more detailed information please contact the DMPT Editorial Office DMPT.Editorial@degruyter.com

We look forward to receiving your manuscript!

Hybrid Open Access

In this journal, authors have the option to publish their article under an open access license. Open Access allows you as an author to retain copyright and share your findings with colleagues and interested parties worldwide without any restraints.
Please note that authors from institutions with which we have a transformative agreement can publish open access without paying an article processing charge (APC). More information on the eligible institutions and articles can be found　under the "Funding and Support" tab HERE.

Editorial

Editor-in-Chief
Adrián LLerena
CICAB Clinical Research Center, Extremadura University Hospital, Badajoz, Spain
allerena@unex.es

Associate Editor
Vangelis G. Manolopoulos, Dept. of Pharmacology, Democritus University of Thrace Medical School, Alexandroupolis, Greece

Managing Editor
Ingrid Fricke-Galindo, Mexico City, Mexcio

Editorial Board
Mongi Benjeddou, Dept. of Biotechnology, University of the Western Cape, Cape Town, South Africa
Bing Chen, Shanghai, Dept. of Laboratory Medicine, Jiaotong University, Shanghai, P.R. China
Jorge Duconge, Medical Center, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico
Jaroslav Hubacek, Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
Magnus Ingelman-Sundberg, Dept. of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
Giorgio D. Kotzalidis, Dept. of Neurosciences, Mental Health, and Sensory Organs, Sapienza University, Rome, Italy
Janja Marc, Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia
Urs A. Meyer, Dept. of Pharmacology, Biocenter of the University of Basel, Basel, Switzerland
Sujit Nair, Pharmaceutical Sciences, University of Mumbai, Mumbai, India
Charity Nofziger, Insitute of Pharmacology and Toxicology, Paracelsus Medical University, Salzburg, Austria
Ana Peiró, University General Hospital of Alicante, Alicante, Spain
Georgia Ragia, Laboratory of Pharmacology, Democritus University of Thrace, Alexandroupolis, Greece
Jae-Gook Shin, Pharmacogenomics Research Center, Inje University College of Medicine, Busan, South Korea
Maurizio Simmaco, Dept. of Neurosciences, Faculty of Medicine & Psychology, Sapienza University of Rome, Rome, Italy
Sanja Stankovic, Faculty of Biology, University of Belgrade, Belgrade, Serbia
Enrique Terán, School of Medicine, Universidad San Francisco de Quito, Quito, Ecuador
Ron H.N. van Schaik, Dept. of Clinical Chemistry, Erasmus Medical Center, Rotterdam, The Netherlands
Sophie Visvikis-Siest, INSERM U525, University of Lorraine, Nancy, France

Editorial Office
Heike Jahnke
Walter de Gruyter GmbH
Genthiner Str. 13, 10785 Berlin, Germany
Tel. +49-30-26005-220; E-mail: dmpt.editorial@degruyter.com

(English)

Online ISSN: 2363-8915
Print ISSN: 2363-8907
Typ: Zeitschrift
Sprache: Englisch
Verlag: De Gruyter
Erstveröffentlichung: 1. Dezember 1980
Erscheinungsweise: 4 Hefte pro Jahr
Zielgruppe: researchers and professionals in the field of pharmacology, basic scientists, translational researchers, industry scientists and professionals in the field of pharmacology